根據(jù)2004年11月發(fā)表在《美國(guó)手術(shù)期刊》的報(bào)道，使用Zyvox治療甲氧苯青霉素耐藥金黃色葡萄球菌感染手術(shù)患者的成功率是87％，而使用萬(wàn)古霉素治療成功率是48％。

手術(shù)部位感染患者有60％的可能在重癥監(jiān)護(hù)室度過(guò)，重新入院治療的可能性增加了5倍，死亡可能增加了2倍。數(shù)據(jù)顯示2000年MRSA導(dǎo)致了美國(guó)醫(yī)院30％手術(shù)部位感染，而1997年只有24％。在該項(xiàng)研究中，大多數(shù)患者接受了靜脈制劑的Zyvox。盡管總體治療時(shí)間相似，但是患者使用Zybox靜脈治療平均時(shí)間顯著少于萬(wàn)古霉素患者（4.7天vs11.1天）

The subset analysis of 135 patients with surgical site infections was taken from a large, randomized, multicenter trial of 1,200 patients designed to compare the clinical efficacy and safety of Zyvox (Pfizer, Inc.).
對(duì)一項(xiàng)比較Zyvox臨床效能與安全性的大規(guī)模隨機(jī)多中心臨床試驗(yàn)1200例患者中的135例手術(shù)部位感染的患者進(jìn)行了亞類分析。

威斯康星州外科副主任、教授、首席研究員John Weiglt教授說(shuō)：“由于MRSA導(dǎo)致的手術(shù)部位感染的流行率不斷增高，早期鑒別MRSA感染以及尋找萬(wàn)古霉素的替代藥物的任務(wù)迫在眉睫，因?yàn)槿魏谓邮苁中g(shù)的患者都處于危險(xiǎn)之中。”

Zyvox Best for MRSA Surgical Site Infections
 
Surgical patients treated for methicillin-resistant Staphylococcus aureus (MRSA) with Zyvox (linesolid) showed success rates of 87% compared to 48% for patients treated with vancomycin, according to a new study published in the December 2004 issue of the American Journal of Surgery.

Patients who develop surgical site infections are 60% more likely to spend time in an intensive care unit, five times more likely to be re-admitted to the hospital, and twice as likely to die. Data show that MRSA caused 30% of surgical site infections in U.S. hospitals in 2000, compared to 24% in 1997. In the study, most patients received the intravenous (IV) formulation of Zyvox. Although the total length of treatment among groups was comparable, the mean duration of IV treatment was significantly shorter for Zyvox patients than for vancomycin patients (4.7 days vs 11.1 days, respectively).

The subset analysis of 135 patients with surgical site infections was taken from a large, randomized, multicenter trial of 1,200 patients designed to compare the clinical efficacy and safety of Zyvox (Pfizer, Inc.).

“As the prevalence of surgical site infections caused by MRSA increases, identifying MRSA early and having alternatives to vancomycin become extremely important, since any patient undergoing surgery is at risk,” said lead investigator Dr. John Weigelt, professor and vice chairman of the department of surgery at the Medical College of Wisconsin (Milwaukee, USA).